Trials / Completed
CompletedNCT05443984
JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis
A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Onconic Therapeutics Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JP-1366 20mg | 1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals) |
| DRUG | Esomeprazole 40mg | 1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals) |
Timeline
- Start date
- 2022-01-17
- Primary completion
- 2023-01-05
- Completion
- 2023-01-05
- First posted
- 2022-07-05
- Last updated
- 2024-08-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05443984. Inclusion in this directory is not an endorsement.